

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SBI HOLDINGS, INC.
(Incorporated in Japan with limited liability)
(Stock code: 6488)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached copy of the Announcement.

On behalf of the Board
SBI Holdings, Inc.
Yoshitaka Kitao
*Representative Director,
President & Chief Executive Officer*

Japan, 26 August 2013

As of the date of this announcement, the executive Directors are Mr Yoshitaka Kitao, Mr Taro Izuchi, Mr Takashi Nakagawa, Mr Tomoya Asakura, Mr Shumpei Morita, Mr Noriaki Maruyama and Mr Peilung Li, the non-executive Directors are Mr Masato Takamura, Mr Hiroshi Tasaka and Mr Teruhide Sato and the independent non-executive Directors are Mr Masaki Yoshida, Mr Kiyoshi Nagano, Mr Keiji Watanabe, Mr Akihiro Tamaki and Mr Masanao Marumono.

Notice Regarding Conclusion of Basic Agreement with King Hamad University Hospital in Bahrain on Clinical Study of 5-aminolevulinic acid

We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*), has entered into a basic agreement with King Hamad University Hospital (Location: Muharraq, Bahrain; “King Hamad University Hospital”) to mutually cooperate in conducting a clinical study on 5-ALA, and the two parties’ common purpose is to improve Bahrain’s medical treatment.

SBI Pharmaceuticals announced in April 2012 that it would promote the 5-ALA business in Bahrain by collaborating with the government of Bahrain. And it is already making preparations jointly with King Hamad University Hospital for a clinical study on photodynamic diagnosis of colorectal cancer that uses 5-ALA. Based on this basic agreement, SBI Pharmaceuticals will also work on clinical studies regarding the diagnosis and treatment of other cancers.

Currently, SBI Pharmaceuticals is also preparing to start a clinical study on diabetes by using 5-ALA at the Diabetes Department of the Bahrain Defense Force Royal Medical Service Hospital, hospitals attached to the Arabian Gulf University, and the Royal College of Surgeons in Ireland - Medical University of Bahrain.

SBI Pharmaceuticals will continue to work closely with the government of Bahrain in accommodating the needs of the country and advancing the business. Simultaneously, we will endeavor to help people around the world stay healthy by further identifying the various possibilities of 5-ALA through pursuing R&D jointly with our partners inside and outside Japan.

King Hamad University Hospital

King Hamad University Hospital, established by King Hamad in 2010, is the second national general hospital in Bahrain and operated by the Bahrain Defense Force. The hospital cooperates with the Ministry of Health of Bahrain in matters regarding related medical centers and first aid and emergency services.

* 5-aminolevulinic acid (5-ALA): An amino acid created in mitochondria. It is an important substance that serves as protein material related to energy production in the form of hemes and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in shochu distillation remnants, red wine and food such as radish sprouts. It is also known as a material forming chloroplasts in plants

For further information, please contact:

SBI Holdings, Inc.: Corporate Communications Dept., Tel: +81 3 6229 0126

SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., Tel: +81 3 6229 0095